

The complexities and challenges of preventing and treating diseases

PLoS Neglected Tropical Diseases

13, e0007083

DOI: [10.1371/journal.pntd.0007083](https://doi.org/10.1371/journal.pntd.0007083)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Discovery of a novel <i>Mycobacterium asiaticum</i> PRA-hsp65 pattern. <i>Infection, Genetics and Evolution</i> , 2019, 76, 104040.	1.0	0
2	Nontuberculous mycobacteria in solid organ transplant. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 476-482.	0.8	11
3	Safety and Efficacy of Nontuberculous Mycobacteria Treatment among Elderly Patients. <i>Medicina (Lithuania)</i> , 2020, 56, 517.	0.8	2
4	Conditional DnaB Protein Splicing Is Reversibly Inhibited by Zinc in Mycobacteria. <i>MBio</i> , 2020, 11, .	1.8	16
5	Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1225-1237.	1.2	8
6	Subspecies-specific sequence detection for differentiation of <i>Mycobacterium abscessus</i> complex. <i>Scientific Reports</i> , 2020, 10, 16415.	1.6	17
7	Efficacy and Mechanisms of Flavonoids against the Emerging Opportunistic Nontuberculous Mycobacteria. <i>Antibiotics</i> , 2020, 9, 450.	1.5	18
8	Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research. <i>Pathogens</i> , 2020, 9, 641.	1.2	13
9	Antimycobacterial Activity of Laurinterol and Aplysin from <i>Laurencia johnstonii</i> . <i>Marine Drugs</i> , 2020, 18, 287.	2.2	8
10	Of tuberculosis and non-tuberculous mycobacterial infections – a comparative analysis of epidemiology, diagnosis and treatment. <i>Journal of Biomedical Science</i> , 2020, 27, 74.	2.6	123
11	Advancement of GyrB Inhibitors for Treatment of Infections Caused by <i>Mycobacterium tuberculosis</i> and Non-tuberculous Mycobacteria. <i>ACS Infectious Diseases</i> , 2020, 6, 1323-1331.	1.8	20
12	The Rise of Non-Tuberculosis Mycobacterial Lung Disease. <i>Frontiers in Immunology</i> , 2020, 11, 303.	2.2	219
13	Targeted Combination Antibiotic Therapy Induces Remission in Treatment-Naïve Crohn's Disease: A Case Series. <i>Microorganisms</i> , 2020, 8, 371.	1.6	17
14	Non-tuberculous mycobacteria and the rise of <i>Mycobacterium abscessus</i> . <i>Nature Reviews Microbiology</i> , 2020, 18, 392-407.	13.6	407
15	The Many Hosts of Mycobacteria 8 (MHM8): A conference report. <i>Tuberculosis</i> , 2020, 121, 101914.	0.8	6
16	Beyond antibiotics for pulmonary nontuberculous mycobacterial disease. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 260-266.	1.2	8
17	In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	36
18	Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models. <i>Biology</i> , 2021, 10, 96.	1.3	54

#	ARTICLE	IF	CITATIONS
19	Identification of Nontuberculous Mycobacteria in Patients with Pulmonary Diseases in Gyeongnam, Korea, Using Multiplex PCR and Multigene Sequence-Based Analysis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-13.	0.7	5
20	Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Scientific Reports, 2021, 11, 9040.	1.6	15
21	Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease. Respiratory Research, 2021, 22, 133.	1.4	32
22	Population genomics provides insights into the evolution and adaptation to humans of the waterborne pathogen Mycobacterium kansasii. Nature Communications, 2021, 12, 2491.	5.8	20
24	Interaction Patterns between Wildlife and Cattle Reveal Opportunities for Mycobacteria Transmission in Farms from North-Eastern Atlantic Iberian Peninsula. Animals, 2021, 11, 2364.	1.0	8
25	First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, e0120821.	1.4	20
26	Water Safety and Health Care. Infectious Disease Clinics of North America, 2021, 35, 667-695.	1.9	10
27	Sensible Functional Linear Discriminant Analysis Effectively Discriminates Enhanced Raman Spectra of <i>Mycobacterium</i> Species. Analytical Chemistry, 2021, 93, 2785-2792.	3.2	15
28	A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex. Frontiers in Microbiology, 2020, 11, 626216.	1.5	13
29	Network approach to mutagenesis sheds insight on phage resistance in mycobacteria. Bioinformatics, 2021, 37, 213-220.	1.8	7
30	Mendelian Susceptibility to Mycobacterial Disease: The First Case of a Diagnosed Adult Patient in the Czech Republic. Case Reports in Immunology, 2020, 2020, 1-5.	0.2	4
31	Non-tuberculous mycobacterial lung disease: a brief review focusing on radiological findings. Revista Da Sociedade Brasileira De Medicina Tropical, 2020, 53, e20200241.	0.4	9
32	Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian Journal of Medical Research, 2020, 152, 185.	0.4	79
33	Hypercalcaemia secondary to disseminated Mycobacterium abscessus and Mycobacterium fortuitum. Journal of the Royal College of Physicians of Edinburgh, The, 2019, 49, 217-221.	0.2	2
34	Nontuberculous mycobacterial disease. , 2019, , 442-446.		0
35	Delayed Nontuberculous Mycobacterium Manifestation 1 Year after a Dog Bite on the Hand. Journal of Wound Management and Research, 2020, 16, 56-58.	0.1	1
36	Mycobacterium abscessus mimicking tubercular spondylodiscitis following ozone therapy: A case report and review of literature. , 2020, 11, 63.		1
37	<i>Mycobacterium abscessus</i> mimicking tubercular spondylodiscitis following ozone therapy: A case report and review of literature. , 0, 11, 63.		0

#	ARTICLE	IF	CITATIONS
38	Pharmacotherapy for nontuberculous mycobacterial pulmonary disease. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 437-445.	0.5	2
39	The key factors contributing to the risk, diagnosis and treatment of non-tuberculous mycobacterial opportunistic infections. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021, 75, 696-710.	0.1	1
40	Role of TlyA in the Biology of Uncultivable Mycobacteria. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	0
41	In silico analysis of promoter regions to identify regulatory elements in TetR family transcriptional regulatory genes of <i>Mycobacterium colombiense</i> CECT 3035. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 53.	1.5	2
42	Distribution of nontuberculous mycobacteria in patients with and without HIV/AIDS in Chongqing. <i>HIV Medicine</i> , 2022, 23, 54-63.	1.0	0
43	A Disseminated <i>Mycobacterium Abscessus</i> Infection in a Patient Affected by Pulmonary Graft versus Host Disease: Case Report with a Revision of Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 2410.	1.0	2
44	Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against <i>Mycobacterium avium</i> infection but is ineffective as an adjunct to antibiotic treatment in chronic disease. <i>Virulence</i> , 2022, 13, 808-832.	1.8	3
45	Novel Screening System of Virulent Strains for the Establishment of a <i>Mycobacterium avium</i> Complex Lung Disease Mouse Model Using Whole-Genome Sequencing. <i>Microbiology Spectrum</i> , 2022, 10, e0045122.	1.2	4
46	Arginine-mediated gut microbiome remodeling promotes host pulmonary immune defense against nontuberculous mycobacterial infection. <i>Gut Microbes</i> , 2022, 14, 2073132.	4.3	21
47	Progression and Dissemination of Pulmonary <i>Mycobacterium Avium</i> Infection in a Susceptible Immunocompetent Mouse Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5999.	1.8	2
48	Comprehensive review of <i>Mycobacterium ulcerans</i> and Buruli ulcer from a bioinformatics perspective – what have we learnt?. <i>Acta Biologica Szegediensis</i> , 2022, 2, 233-245.	0.7	1
49	<i>Mycobacterium abscessus</i> : insights from a bioinformatic perspective. <i>Critical Reviews in Microbiology</i> , 2023, 49, 499-514.	2.7	2
50	Doubled Nontuberculous Mycobacteria Isolation as a Consequence of Changes in the Diagnosis Algorithm. <i>Infection and Drug Resistance</i> , 0, Volume 15, 3347-3355.	1.1	5
51	<i>Mycobacterium abscessus</i> : It's Complex. <i>Microorganisms</i> , 2022, 10, 1454.	1.6	18
52	In vitro and intracellular inhibitory activities of nosiheptide against <i>Mycobacterium abscessus</i> . <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
53	<i>In Vitro</i> Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	3
54	Evaluation of MALDI Biotyper Mycobacteria Library for Identification of Nontuberculous Mycobacteria. <i>Journal of Clinical Microbiology</i> , 2022, 60, .	1.8	5
55	Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria. <i>Theranostics</i> , 2022, 12, 6848-6864.	4.6	2

#	ARTICLE	IF	CITATIONS
56	Noncanonical Mismatch Repair Protein NucS Modulates the Emergence of Antibiotic Resistance in <i>Mycobacterium abscessus</i> . <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
57	A rare infective cause for recurrent exacerbations and poor asthma control – <i>Mycobacterium kumamotoense</i> . <i>JRSM Open</i> , 2022, 13, 205427042211240.	0.2	0
58	Clinical characteristics of nontuberculous mycobacterial disease in people living with HIV/AIDS in South Korea: A multi-center, retrospective study. <i>PLoS ONE</i> , 2022, 17, e0276484.	1.1	4
59	<i>In Vitro</i> Profiling of the Synthetic RNA Polymerase Inhibitor MMV688845 against <i>Mycobacterium abscessus</i> . <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
60	Immunogenicity and protection against <i>Mycobacterium avium</i> with a heterologous RNA prime and protein boost vaccine regimen. <i>Tuberculosis</i> , 2023, 138, 102302.	0.8	4
61	Potential Use of <i>Mycobacterium paragordoniae</i> for Antimycobacterial Drug Screening Systems. <i>Journal of Microbiology</i> , 2023, 61, 121-129.	1.3	1
63	Drug Discovery for Non-tuberculous Mycobacteria: Recent Updates. <i>Integrated Science</i> , 2023, , 571-600.	0.1	1
64	In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2023, 50, 604-609.	0.9	3